SCHEMBL2310430

SCHEMBL2310430

CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(/C=C/c4csc5c(N)ncnc45)c3)cc2C(F)(F)F)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K7 O43318 6/20 0.59
MAP4K2 Q12851 6/20 0.59
MAPK14 Q16539 6/20 0.59
MAP3K20 Q9NYL2 2/20 0.59
SRC P12931 2/20 0.59
MAP4K4 O95819 1/20 0.59
ABL1 P00519 1/20 0.59
RAF1 P04049 1/20 0.59
LYN P07948 1/20 0.59
EPHA2 P29317 1/20 0.59
EPHB2 P29323 1/20 0.59
CSK P41240 1/20 0.59
ABL2 P42684 1/20 0.59
EPHB4 P54760 1/20 0.59
HCK P08631 4/20 0.58
NR2C2 P49116 4/20 0.58
MAPK1 P28482 1/20 0.57
HTT P42858 1/20 0.57
ATM Q13315 1/20 0.57
FES P07332 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14718038 1.00 MAP3K7 (0.59) MAP3K7MAP4K2MAPK14MAP3K20SRC
SCHEMBL14717718 0.97 MAP3K7 (0.62) MAP3K7MAP4K2MAPK14MAP3K20SRC
SCHEMBL12433018 0.97 MAP3K7 (0.62) MAP3K7MAP4K2MAPK14MAP3K20SRC
SCHEMBL19073533 0.89 MAP3K7 (0.52) MAP3K7MAP4K2MAPK14MAP3K20SRC
SCHEMBL2317748 0.86 MAPK1 (0.65) HCKNR2C2MAPK1HTTATM
SCHEMBL2314878 0.85 ATM (0.69) RAF1EPHA2HCKNR2C2MAPK1
SCHEMBL2311744 0.82 BRAF (0.60) MAP3K7MAP4K2SRCABL1RAF1
SCHEMBL14717654 0.82 BRAF (0.60) MAP3K7MAP4K2SRCABL1RAF1
SCHEMBL2358087 0.80 MAPK14 (0.60) MAPK14ABL1RAF1DDR1BRAF
SCHEMBL2318942 0.80 MAPK14 (0.60) MAPK14ABL1RAF1DDR1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528925-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO LTD (KR) 2017-07-05 EP claimed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US claimed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US claimed
EP-2528925-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO LTD (KR) 2017-07-05 EP disclosed
EP-2528925-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO LTD (KR) 2017-07-05 EP disclosed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US disclosed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US disclosed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US disclosed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US disclosed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US disclosed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US disclosed
EP-2528925-A2 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES Hanmi Science Co., Ltd. (KR) 2012-12-05 EP disclosed
WO-2011093684-A2 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI HOLDINGS CO., LTD. (KR) 2011-08-04 WO disclosed
WO-2011093684-A2 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI HOLDINGS CO., LTD. (KR) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES CDK2, TK1, DTYMK MAP3K7 13/4885MAP4K2 4/4885MAPK14 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.